{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:17:06Z","timestamp":1788175026936,"version":"build-2803163510"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The expansion of targeted therapies and the widespread adoption of treat-to-target strategies have substantially improved outcomes for rheumatoid arthritis (RA). However, patient populations remain highly heterogeneous in routine clinical practice. This diversity makes risk-stratified therapeutic selection and shared decision-making essential, particularly when accounting for infection risk, cardiovascular disease, malignancy, thromboembolism, and reproductive considerations. This paper reviews current standard-of-care management and unmet needs while highlighting three priority challenges that may represent future inflection points. First, it proposes a framework for reappraising the pathophysiology of treatment-refractory disease. This model captures the discordance between inflammation and symptoms through persistent inflammatory refractory RA and non-inflammatory refractory RA constructs, while explicitly incorporating reasons for treatment discontinuation. Second, the text addresses the identification of high-risk populations across the continuum from preclinical to early RA and discusses monitoring strategies designed to minimize the risk of overtreatment. Finally, it delineates barriers to implementing precision medicine, including limited access to local biospecimens, challenges in outcome definitions, and complexities in trial design. The paper then outlines a pragmatic, phased roadmap to overcome these hurdles. Translating these concepts into clinical practice would extend and refine conventional treat-to-target paradigms. This approach offers a pathway toward more optimized and individualized therapeutic strategies.<\/jats:p>","DOI":"10.1093\/mr\/roag033","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:21:15Z","timestamp":1774869675000},"page":"665-672","source":"Crossref","is-referenced-by-count":0,"title":["Rheumatoid arthritis at a turning point in the era of targeted therapies"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9693-9263","authenticated-orcid":false,"given":"Satoshi","family":"Kubo","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan , Kitakyushu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"2026083106415682500_ref1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026083106415682500_ref2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026083106415682500_ref3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026083106415682500_ref4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026083106415682500_ref5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026083106415682500_ref6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2026.01.023","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update","author":"Smolen","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"2026083106415682500_ref7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2026083106415682500_ref8","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026083106415682500_ref9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/mr\/roaf006","article-title":"2024 update of the Japan college of rheumatology clinical practice guidelines for the Management of Rheumatoid Arthritis: secondary publication","volume":"35","author":"Harigai","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026083106415682500_ref10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/mr\/roac089","article-title":"Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance","volume":"33","author":"Takagi","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026083106415682500_ref11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2026083106415682500_ref12","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026083106415682500_ref13","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026083106415682500_ref14","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/ard-2022-223528","article-title":"Unmet need in rheumatology: reports from the advances in targeted therapies meeting, 2022","volume":"82","author":"Winthrop","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026083106415682500_ref15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026083106415682500_ref16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41584-020-00541-7","article-title":"Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis","volume":"17","author":"Buch","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"2026083106415682500_ref17","article-title":"Difficult-to-treat rheumatoid arthritis (part 1): systematic review and meta-analysis on global prevalence","volume":"85","author":"Xie","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026083106415682500_ref18","doi-asserted-by":"crossref","first-page":"e002842","DOI":"10.1136\/rmdopen-2022-002842","article-title":"Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease","volume":"9","author":"Leon","year":"2023","journal-title":"RMD Open"},{"key":"2026083106415682500_ref19","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1093\/rheumatology\/kead143","article-title":"Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital","volume":"62","author":"Hecquet","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026083106415682500_ref20","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1093\/rheumatology\/keab209","article-title":"Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice","volume":"60","author":"Takanashi","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026083106415682500_ref21","doi-asserted-by":"crossref","first-page":"e003808","DOI":"10.1136\/rmdopen-2023-003808","article-title":"Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with \u2018difficult to treat\u2019 rheumatoid arthritis","volume":"10","author":"Bertsias","year":"2024","journal-title":"RMD Open"},{"key":"2026083106415682500_ref22","doi-asserted-by":"crossref","first-page":"e006544","DOI":"10.1136\/rmdopen-2025-006544","article-title":"Predicting the progression of difficult-to-treat rheumatoid arthritis by a machine learning scoring system, from the FIRST registry","volume":"12","author":"Ueno","year":"2026","journal-title":"RMD Open"},{"key":"2026083106415682500_ref23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13075-023-03165-w","article-title":"Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry","volume":"25","author":"Jung","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"2026083106415682500_ref24","doi-asserted-by":"crossref","first-page":"e006513","DOI":"10.1136\/rmdopen-2025-006513","article-title":"Real-world effectiveness of b\/tsDMARD switching in low-inflammatory difficult-to-treat rheumatoid arthritis: insights from the FIRST registry","volume":"12","author":"Sakai","year":"2026","journal-title":"RMD Open"},{"key":"2026083106415682500_ref25","doi-asserted-by":"crossref","first-page":"e006271","DOI":"10.1136\/rmdopen-2025-006271","article-title":"Strengths and limitations of the EULAR definition for difficult-to-treat rheumatoid arthritis","volume":"11","author":"Nagy","year":"2025","journal-title":"RMD Open"},{"key":"2026083106415682500_ref26","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2026083106415682500_ref27","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41588-022-01213-w","article-title":"Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis","volume":"54","author":"Ishigaki","year":"2022","journal-title":"Nat Genet"},{"key":"2026083106415682500_ref28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41590-021-01093-y","article-title":"Congenital iRHOM2 deficiency causes ADAM17 dysfunction and environmentally directed immunodysregulatory disease","volume":"23","author":"Kubo","year":"2022","journal-title":"Nat Immunol"},{"key":"2026083106415682500_ref29","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2026083106415682500_ref30","doi-asserted-by":"crossref","first-page":"e001085","DOI":"10.1136\/rmdopen-2019-001085","article-title":"Recherche clinique en rhumatismes i. Measuring ACPA in the general population or primary care: is it useful?","volume":"6","author":"Finckh","year":"2020","journal-title":"RMD Open"},{"key":"2026083106415682500_ref31","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/annrheumdis-2016-209846","article-title":"EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis","volume":"76","author":"Steenbergen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026083106415682500_ref32","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.ard.2025.01.021","article-title":"EULAR\/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia","volume":"84","author":"Steenbergen","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026083106415682500_ref33","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(23)02650-8","article-title":"Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial","volume":"403","author":"Rech","year":"2024","journal-title":"Lancet"},{"key":"2026083106415682500_ref34","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","article-title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial","volume":"403","author":"Cope","year":"2024","journal-title":"Lancet"},{"key":"2026083106415682500_ref35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","article-title":"Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study","volume":"78","author":"Gerlag","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026083106415682500_ref36","doi-asserted-by":"crossref","DOI":"10.1002\/art.43366","article-title":"A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis","volume":"78","author":"Deane","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"2026083106415682500_ref37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(22)01193-X","article-title":"Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial","volume":"400","author":"Krijbolder","year":"2022","journal-title":"Lancet"},{"key":"2026083106415682500_ref38","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMra1615014","article-title":"Classification, ontology, and precision medicine","volume":"379","author":"Haendel","year":"2018","journal-title":"N Engl J Med"},{"key":"2026083106415682500_ref39","doi-asserted-by":"crossref","first-page":"k4245","DOI":"10.1136\/bmj.k4245","article-title":"Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects","volume":"363","author":"Kent","year":"2018","journal-title":"BMJ"},{"key":"2026083106415682500_ref40","first-page":"447","article-title":"A wide perspective of targeted therapies for precision medicine in autoimmune diseases","volume":"5","author":"Miyagawa","year":"2020","journal-title":"Expert Rev Precis Me"},{"key":"2026083106415682500_ref41","doi-asserted-by":"crossref","first-page":"e70239","DOI":"10.1111\/1756-185X.70239","article-title":"Pursuing precision medicine in managing rheumatoid arthritis","volume":"28","author":"Kubo","year":"2025","journal-title":"Int J Rheum Dis"},{"key":"2026083106415682500_ref42","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N Engl J Med"},{"key":"2026083106415682500_ref43","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJMp1114866","article-title":"Preparing for precision medicine","volume":"366","author":"Mirnezami","year":"2012","journal-title":"N Engl J Med"},{"key":"2026083106415682500_ref44","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41584-022-00845-w","article-title":"Precision medicine: the precision gap in rheumatic disease","volume":"18","author":"Lin","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2026083106415682500_ref45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41584-023-00948-y","article-title":"Precision medicine in systemic lupus erythematosus","volume":"19","author":"Fasano","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2026083106415682500_ref46","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/rheumatology\/keab448","article-title":"Precision medicine in autoimmune diseases: fact or fiction","volume":"60","author":"Toro-Dominguez","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026083106415682500_ref47","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"key":"2026083106415682500_ref48","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2665-9913(23)00241-2","article-title":"Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials","volume":"5","author":"Rivellese","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2026083106415682500_ref49","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-023-06708-y","article-title":"Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes","volume":"623","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"2026083106415682500_ref50","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0140-6736(22)01390-3","article-title":"Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials","volume":"400","author":"Chihara","year":"2022","journal-title":"Lancet"},{"key":"2026083106415682500_ref51","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/ard-2024-226228","article-title":"Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness","volume":"84","author":"Kubo","year":"2025","journal-title":"Ann Rheum Dis"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag033\/67691564\/roag033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/5\/665\/67691564\/roag033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/5\/665\/67691564\/roag033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:42:15Z","timestamp":1788172935000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/5\/665\/8566162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":51,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3,31]]},"published-print":{"date-parts":[[2026,8,31]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roag033","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,3,31]]}}}